COSTEM 2019 | Can third party CMV-specific T-cells replace drug therapy?

Per Ljungman

Per Ljungman, MD, PhD, Karolinska University Hospital, Solna, Sweden, evaluates third-party CMV-specific T-cells replacing drug therapy. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

Share this video  
Similar topics